<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124304">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789073</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-146</org_study_id>
    <nct_id>NCT01789073</nct_id>
  </id_info>
  <brief_title>Preoperative Oral Immunonutrition for Patients With Pancreatic Cancer Undergoing Elective Surgery - Effect on Complications and Length of Hospital Stay</brief_title>
  <official_title>Randomized, Controlled Trial Investigating the Effect of Preoperative Oral Immunonutrition on Complications and Length of Hospital Stay After Elective Surgery for Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <authority>Denmark: &quot;The National Ethical Commitee  under The Ministry of health and prevention&quot;.</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of preoperative immunonutrition on
      complications and length of hospital stay in patients with pancreatic cancer undergoing
      elective surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Overall postoperative complications after major gastrointestinal (GI) elective surgery.</measure>
    <time_frame>Within the first 30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay after major gastrointestinal (GI) elective surgery</measure>
    <time_frame>Within the first 30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight stability, functional capability and patients´ satisfaction with the overall study course.</measure>
    <time_frame>from recruitment and within 30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Impact, Nestlé Health Science</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Impact-arm receives the intervention the last 7 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control-arm receives no intervention but is treated according to the standard procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Impact, Nestlé Health Science</intervention_name>
    <description>Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.</description>
    <arm_group_label>Oral Impact, Nestlé Health Science</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women referred to treatment at Surgical Gastroenterology Clinic C, Ward 2122
             for pancreatic cancer

          -  Age &gt; 18 years.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnant and lactating women

          -  Persons who cannot understand and/or speak Danish

          -  Renal dysfunction

          -  Milk allergy

          -  Participants are excluded if elective surgery is not indicated after all
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens R Andersen, Chief Phys., Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgical Gastroenterology Clinic C, Ward 2122, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Arne Astrup</investigator_full_name>
    <investigator_title>Chief of Institute of Human Nutrition</investigator_title>
  </responsible_party>
  <keyword>Postoperative</keyword>
  <keyword>Complications</keyword>
  <keyword>Elective</keyword>
  <keyword>Surgery</keyword>
  <keyword>GI surgery</keyword>
  <keyword>Immunonutrition</keyword>
  <keyword>Immune-enhancing</keyword>
  <keyword>Immune-modulating</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Postoperative complications and length of hospital stay after major gastrointestinal (GI) elective surgery.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
